OncLive TV

Neeta Somaiah, MD, discusses chemotherapy as the current mainstay of treatment in sarcoma subtypes and the emergence of immunotherapies in the space.

Mazyar Shadman, MD, MPH, discusses the need for a clinical consensus in selecting optimal treatment strategies in diffuse large B-cell lymphoma.

Rami Komrokji, MD, discusses the importance of establishing a clinical consensus to standardize the use of molecular testing in myelodysplastic syndromes.

Amrita Krishnan, MD, discusses the challenges in developing a clinical consensus on risk stratification in smoldering multiple myeloma and its role in guiding treatment decisions.

Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

Elizabeth A. Brem, MD, highlights upcoming changes in the follicular lymphoma treatment paradigm that could move the field beyond chemotherapy.

Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen margin assessment in soft tissue sarcoma.

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Rohan Garje, MD, discusses clinical outcomes among patients with invasive primary urethral cancer based on varying treatment approaches and histology.

Sia Daneshmand MD, discusses key efficacy findings from the SunRISE-1 trial of TAR-200 in patients with BCG-unresponsive, high-risk NMIBC with CIS.

D. Ross Camidge, MD, PhD, discusses the benefits of biomarker testing and the potential value of longitudinal testing in non–small cell lung cancer.

Sapna Patel, MD, discusses the potential for adjuvant immunotherapy in patients with high-risk cutaneous squamous cell carcinoma.

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.

Claire Harrison, MD, FRCP, FRCPath, discusses ongoing research with first-line JAK inhibitors for patients with myelofibrosis.

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Katherine L. Nathanson, MD, discusses the next steps for identifying novel mechanisms of resistance beyond reversion mutations in breast cancer.

Martin Dreyling, MD, discusses updated safety results from the randomized phase 3 TRIANGLE trial in younger patients with lower-risk MCL.

Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.

Francisco J. Hernandez-Ilizaliturri, MD, details the clinical implications of venetoclax for the treatment of patients with CLL regarding T-cell repair.

Pankit Vachhani, MD, discusses the rationale for evaluating navtemadlin as an add-on to ruxolitinib in myelofibrosis after a suboptimal response to ruxolitinib alone.

Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.

Susumu Hijioka, MD, PhD, discusses the efficacy of first-line everolimus plus lanreotide in patients with unresectable or recurrent GEP-NETs.

Filippo Pietrantonio, MD, discusses updated efficacy with amivantamab as monotherapy and in combination with chemotherapy in metastatic colorectal cancer.

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Olalekan Oluwole, MD, MPH, discusses the incidence and resolution of CRS and neurological events beyond two weeks following axi-cel infusion in relapsed/refractory LBCL.

Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.